Donanemab + Aducanumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mild Cognitive Impairment (MCI)
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease
Trial Timeline
Nov 16, 2021 → Sep 19, 2023
NCT ID
NCT05108922About Donanemab + Aducanumab
Donanemab + Aducanumab is a phase 3 stage product being developed by Eli Lilly for Mild Cognitive Impairment (MCI). The current trial status is completed. This product is registered under clinical trial identifier NCT05108922. Target conditions include Mild Cognitive Impairment (MCI), Alzheimer Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05108922 | Phase 3 | Completed |
Competing Products
20 competing products in Mild Cognitive Impairment (MCI)